A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
Status:
Completed
Trial end date:
2019-07-05
Target enrollment:
Participant gender:
Summary
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid
tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2
dose of ABBV-075 at different monotherapy dosing schedules. In addition the study will
evaluate the safety. tolerability and the pharmacokinetics of ABBV-075 monotherapy or
combination therapy in disease specific expansion cohorts.